TY - JOUR ID - 87912 TI - Cost-Effectiveness Analysis of Human Papillomavirus Vaccination in Adolescent Girls in Taiwan JO - Asian Pacific Journal of Cancer Prevention JA - APJCP LA - en SN - 1513-7368 AU - Tang, Chao-Hsiun AU - Cheng, Wen Fang AU - Jiang, Jhih-Hua AU - You, San Lin AU - Huang, Lee-Wen AU - Hsieh, Jui-Yu AU - Mukherjee, Piyali AU - Van Kriekinge, Georges AU - Lee, Christa AD - School of Health Care Administration, Taipei Medical University, Taipei, Taiwan. AD - Department of Obstetrics and Gynecology, College of Medicine, National Taiwan University, Taipei, Taiwan. AD - School of Medicine, College of Medicine, Big Data Research Centre, Fu-Jen Catholic University, New Taipei City, Taiwan. AD - Department of Obstetrics and Gynecology, Shin Kong Wu Ho-Su Memorial Hospital, Taipei, Taiwan. AD - GSK, Taipei, Taiwan. AD - GSK, Singapore, Singapore. AD - GSK, Wavre, Belgium. Y1 - 2019 PY - 2019 VL - 20 IS - 5 SP - 1377 EP - 1387 KW - HPV vaccination KW - Cervical cancer KW - Taiwan KW - Cost-Effectiveness DO - 10.31557/APJCP.2019.20.5.1377 N2 - Objective: Three vaccines are available to Taiwanese young girls for cervical cancer (CC) prevention. Herewe evaluate the cost-effectiveness of the two-dose (2D) AS04-adjuvanted HPV-16/18 vaccine (2D-AS04-HPV-16/18v)+screening compared with a screening programme alone, with 2D human papillomavirus 6/11/16/18 vaccine(2D-4vHPVv)+screening, and with 2D/three-dose (3D) human papillomavirus 6/11/16/18/31/33/45/52/58 vaccine(9vHPVv)+screening, for Taiwan universal mass vaccination. Methods: A static Markov cohort model simulated thenatural history of human papillomavirus (HPV) infection and CC screening for a 12-year-old cohort of Taiwanese girls(N=120,000). The model ran in 1-year cycles over the cohort’s lifetime. Vaccine efficacy irrespective of HPV typewas considered in the analysis for each vaccine. Input data were obtained from published literature, local databases,government reports and websites, and expert opinion. The analysis incorporated direct medical costs only, with anannual discount rate of 3.0%. The threshold was determined as 1 Gross Domestic Product per capita (New Taiwandollar [NT$] 727,818; year 2016). Results: The 2D-AS04-HPV-16/18v+screening yielded 0.0365 quality-adjusted lifeyear (QALY) gained at an additional cost of NT$ 5,770 per person compared with the screening programme alone. Thisresulted in an incremental cost-effectiveness ratio well below the threshold. Compared with 2D-4vHPVv+screening and2D/3D-9vHPVv+screening, discounted results demonstrated additional QALYs gained at lower cost for 2D-AS04-HPV-16/18v+screening, making it dominant over both 2D-4vHPVv+screening and 2D/3D-9vHPVv+screening. Conclusions:Vaccinating Taiwanese girls with 2D-AS04-HPV-16/18v in addition to screening to prevent CC is cost-effectivecompared with using a screening programme alone and the dominant option compared with 2D-4vHPVv+screeningand 2D/3D-9vHPVv+screening. UR - https://journal.waocp.org/article_87912.html L1 - https://journal.waocp.org/article_87912_9392c2c6b705db65c5227ad0a6918eb2.pdf ER -